The agency said that although the Akeega with prednisone improved outcomes in all patients with HRR mutations, the benefits were driven by those with BRCA2 mutations.

The FDA approved niraparib and abiraterone acetate plus prednisone for BRCA2-mutated mCSPC, based on the AMPLITUDE trial's rPFS results. FDA approves a new treatment combining niraparib and ...

The FDA approved Akeega combination therapy for adults with BRCA2-mutated metastatic castration-sensitive prostate cancer.

TARGETED treatments for prostate cancer were a central theme at the European Society for Medical Oncology (ESMO) Congress ...

Trastuzumab deruxtecan (T-DXd; Enhertu), is a HER2-targeting ADC that is used in ET-treated HER2-low or HER2-ultralow disease ...

Abstract: Recombination of excess charge carriers in semiconductors occurring in emitter layers or at the interface to dielectric layers is typically assessed via injection-dependent lifetime ...

When DNA breaks, cells must repair it accurately to prevent harmful mutations. Researchers have discovered that during a key ...

When DNA breaks, cells must repair it accurately to prevent harmful mutations. Researchers have discovered that during a key repair process called ...

When DNA breaks, cells must repair it accurately to prevent harmful mutations. Researchers have discovered that during a key repair process called homologous recombination, the cell uses loops in its ...

This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...